Nutra Pharma Corp. Completes Acquisition of Bio Therapeutics, Inc.

Business Editors & Health/Medical Writers

PLANTATION, Fla.--(BUSINESS WIRE)--Aug. 22, 2002

Nutra Pharma Corp. (OTCBB:NPHC):

Proteomics has the potential to revolutionize the development of clinical diagnostics and pharmaceutical therapeutics. Acquisition of Bio Therapeutics brings Nutra Pharma closer to understanding the activity of protein systems and the underlying characteristics of disease and wellness.

Nutra Pharma Corp. (OTCBB:NPHC) announced today that it has completed its acquisition of 100 percent of the capital stock of Bio Therapeutics Inc. Bio Therapeutics shareholders will receive one share of Nutra Pharma common stock for every share of Bio Therapeutics common stock.

"The acquisition of Bio Therapeutics Inc. gives Nutra Pharma a strong patent portfolio, effective drug delivery mechanisms and a host of drug candidates to build upon," said Dr. Harold Crews, Nutra Pharma's Chief Executive Officer. "We will focus on completing clinical trials for our Multiple Sclerosis drug, licensing our patented drug delivery mechanisms and monetizing our patented peptide-altering platform technologies," he added.

Bio Therapeutics' 19 years of work in the field of protein pharmaceutical development adds to Nutra Pharma's growing portfolio of drug and therapeutic candidates. The focus on protein-based drugs is due to the fact that proteins regulate the activities of cells, tissues, organs and interactions between them that trigger chemical reactions in cells. Abnormalities in protein production or function have been connected to many diseases, including cancer and AIDS.

Proteomics is the study of the location, interaction, structure and function of proteins and aims to identify the proteins present in normal and diseased tissues. While the Human Genome Project opens the door for new scientific discoveries, it does not reveal the cause of a disease, nor does it identify specific targets for treatment. Proteomics aims to identify and characterize the proteins present in normal and diseased biological samples, enabling researchers to design new drugs and treatments.

Bio Therapeutics' research has yielded a breakthrough class of therapeutic peptides collectively referred to as "Immunokines." This patented peptide technology has created new opportunities for the relief and treatment of a variety of devastating neurological and viral disorders, most of which are currently without satisfactory therapies.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharma company focused on the optimization of protein compounds in order to achieve maximum therapeutic practicability (enhanced efficacy, minimized toxicity and ease of administration). The company is engaged in the discovery and development of novel peptide therapeutics and drug delivery systems for the treatment of several different human and companion animal diseases. Nutra Pharma's core technology revolves around the derivation of specialized receptor-binding peptides from natural proteins and peptides found in nature. Product candidates include Multiple Sclerosis, HIV, Herpes, Hepatitis C and Cancer.

This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Nutra Pharma Corp., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.